India

HOLD (no change)

Consensus ratings*: Buy 25	Hold 7 Sell 6
Current price:	Rs1,575
Target price:	Rs1,643
Previous target:	Rs1,479
Up/downside:	4.3%
InCred Research / Consensus	s: 7.9%
Reuters:	
Bloomberg:	CIPLA IN
Market cap:	US\$17,515m
	Rs1,271,841m
Average daily turnover:	US\$37.2m
	Rs2698.4m
Current shares o/s:	807.0m
Free float: *Source: Bloomberg	66.5%

Key changes in this note

Reset our FY25F/26F EPS by +4%/+2%.



Cipla Ltd

In-line 1Q – US biz shines, India misses

- Decent 1QFY25 performance. Margins came in at the higher end of the guidance at 25.6%, around 100bp above expectations.
- India business was hit by a change in distribution model for trade generics. US market posted a strong 11% QoQ growth at US\$250m, 10% above estimate.
- FY25F/26F earnings reset by +4%/+2%. Given the moderate earnings growth going ahead, we retain HOLD with a target price of Rs1,643 (Rs1,479 earlier).

Broadly, an in-line set of numbers

Cipla's 1QFY25 operational profits exceeded expectations, with gross margin up 50bp QoQ, driven by a superior product mix (gLanreotide channel filing in the US). The EBITDA margin at 25.6% was 100bp above estimate, reflecting the sales mix & operational efficiency. US revenue grew by 11% QoQ to US\$250m, surpassing the US\$228m estimate, boosted by a 4% market share gain in gAlbuterol, higher sales of gRevlimid and channel filling in gLanreotide. South Africa saw a 19% YoY revenue increase in constant currency or CC terms, driven by the private market. In India, revenue rose by 4.5% YoY, below the 9% estimate, due to distribution model change in the trade generics business. R&D spending increased by 20bp YoY to 5.3% of sales due to product development costs. Reported PAT at Rs11.8bn was 4% above estimate.

US sales should sustain around US\$235-240m through FY25F

Cipla expects to sustain quarterly run-rate of US\$235-240m in the US through the year, as gLanreotide sales to come off in the coming quarters, given the high channel filling in 1QFY25. Nevertheless, we believe this itself is a very strong run-rate. Sales ramp-up in gLanreotide will be gradual, as the manufacturing partner is facing supply problems. Cipla expects to launch two more peptide products in CY24F, and another one in CY25F. It expects to file for gAdvair from Invagen by the end of CY24F while for gAbraxane it will depend on the US Food and Drug Administration's (USFDA) re-inspection of the Goa plant; we currently factor in a 4QFY26F launch for both gAdvair and gAbraxane. In India, the transition to the new distribution model is complete and trade generics business should recover from 2QFY25F.

Retain HOLD rating

We expect the next two years to be relatively moderate for Cipla, with a 9% CAGR led by delay in key launches (gAdvair, gAbraxane). We thus expect the stock to be range-bound in the medium term. Our FY25F/26F earnings estimates stand increased by 4%/2%, respectively, baking in higher margins. Retain HOLD rating on the stock with a higher target price of Rs1,643 (Rs1,479 earlier). Upside risks: USFDA clearance to Goa & Indore plants and faster-than-expected product launch. Vice-versa on the downside.

Financial Summary	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Revenue (Rsm)	217,633	227,531	257,741	275,057	299,651
Operating EBITDA (Rsm)	44,953	50,270	62,910	69,283	76,571
Net Profit (Rsm)	25,168	28,019	41,343	46,294	51,140
Core EPS (Rs)	32.3	36.3	53.0	57.4	63.4
Core EPS Growth	12.2%	12.3%	45.9%	8.3%	10.5%
FD Core P/E (x)	48.73	43.38	29.72	27.46	24.85
DPS (Rs)	5.0	8.5	5.5	6.0	6.0
Dividend Yield	0.32%	0.54%	0.35%	0.38%	0.38%
EV/EBITDA (x)	28.06	25.06	20.05	17.22	15.07
P/FCFE (x)	21.35	23.92	18.39	8.50	14.93
Net Gearing	(4.1%)	(3.6%)	(1.5%)	(23.6%)	(31.6%)
P/BV (x)	6.10	5.43	4.76	4.12	3.59
ROE	13.3%	13.2%	17.1%	16.1%	15.4%
% Change In Core EPS Estimates				(1.49%)	
InCred Research/Consensus EPS (x)					

Research Analyst(s)



Praful BOHRA T (91) 22 4161 1552 E praful.bohra@incredresearch.com Yogesh SONI T (91) 8850099267 E yogesh.soni@incredresearch.com

SOURCE: INCRED RESEARCH, COMPANY REPORTS

InCred Equities

Revenue53,75258,28558,10157,39363,28966,78266,03861,63266,5Consumption of raw materials20,24421,60220,04320,63422,36823,13122,19520,50121,5as % of sales37.7%37.1%34.5%36.0%35.3%34.6%33.6%33.3%32.Employee costs9,5579,6089,4879,64810,66610,91110,68110,84211,7Other expenditure1251714052144961537415316154021168612690123as % of sales23.3%24.1%24.9%26.8%24.2%23.1%17.7%20.6%18.EBITDA11,43413,02314,07611,73714,93917,33817,47513,15917,Margins (%)21.3%22.3%24.2%23.6%26.0%26.5%21.4%25.Other income1,0341,2301,1441,3461,3631,7631,8462,4931,Interest17825631834416425830117676PBT9,74611,00412,1819,27813,74615,94216,68612,59316,Total tax2,6803,0264,1002,2233,7804,3844,0533,2494,Adj. PAT before extraordinary items6,8647,8898,0107,0559,96611,55812,6339,39411,Mi	re 1: Financial summary											
Consumption of raw materials20,24421,60220,04320,63422,36823,13122,19520,50121,3as % of sales37.7%37.1%34.5%36.0%35.3%34.6%33.6%33.3%32.Employee costs9,5579,6089,4879,64810,66610,91110,68110,84211,3as % of sales17.8%16.5%16.3%16.8%16.9%16.3%16.2%17.6%17.Other expenditure1251714052144961537415316154021168612690122as % of sales23.3%24.1%24.9%26.8%24.2%23.1%17.7%20.6%18.EBITDA11,43413,02314,07611,73714,93917,33817,47513,15917,Margins (%)21.3%22.3%24.2%20.5%23.6%26.0%26.5%21.4%25.Depreciation2,5442,9942,7213,4622,3922,9002,3342,8832,4Other income1,0341,2301,1441,3631,7631,8462,4931,6Interest178256318344164258301176176Total tax2,6803,0264,1002,2233,7804,3844,0533,2494,33Minority interest(MI)-202-89-7125-9-249146Adj. PAT before extraordinary items6	n)	1QFY23 2	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	Y-o-Y (%)	Q-o-Q (%)
as % of sales 37.7% 37.1% 34.5% 36.0% 35.3% 34.6% 33.6% 33.3% 32. Employee costs 9,557 9,608 9,487 9,648 10,666 10,911 10,681 10,842 11,9 as % of sales 17.8% 16.5% 16.3% 16.8% 16.9% 16.3% 16.2% 17.6% 17.7% 17.6% 17.7% Other expenditure 12517 14052 14496 15374 15316 15402 11686 12690 123 as % of sales 23.3% 24.1% 24.9% 26.8% 24.2% 23.1% 17.7% 20.6% 18. EBITDA 11,434 13,023 14,076 11,737 14,939 17,475 13,159 17,7 Margins (%) 21.3% 22.3% 24.2% 20.5% 23.6% 26.0% 26.5% 21.4% 25. Depreciation 2,544 2,994 2,721 3,462 2,392 2,900 2,334 2,883 2,4 Other income 1,034 1,230 1,144 1,363	nue	53,752	58,285	58,101	57,393	63,289	66,782	66,038	61,632	66,939	6%	9%
Employee costs9,5579,6089,4879,64810,66610,91110,68110,84211,as % of sales17.8%16.5%16.3%16.8%16.9%16.3%16.2%17.6%17.Other expenditure1251714052144961537415316154021188612690122as % of sales23.3%24.1%24.9%26.8%24.2%23.1%17.7%20.6%18.EBITDA11,43413,02314,07611,73714,93917,33817,47513,15917,7Margins (%)21.3%22.3%24.2%20.5%23.6%26.0%26.5%21.4%25.Depreciation2,5442,9942,7213,4622,3922,9002,3342,8832,4Other income1,0341,2301,1441,3461,3631,7631,8462,4931,6Interest1782563183441642583011767PBT9,74611,00412,1819,27813,74615,94216,68612,59316,7Total tax2,6803,0264,1002,2233,7804,3844,0533,2494,5Tax rate (%)27.5%27.5%33.7%24.0%27.5%27.5%24.3%25.8%27.PAT before MI7,0667,9788,0817,0559,96611,55812,6339,34411,1Minority interest(MI)-202 </td <td>umption of raw materials</td> <td>20,244</td> <td>21,602</td> <td>20,043</td> <td>20,634</td> <td>22,368</td> <td>23,131</td> <td>22,195</td> <td>20,501</td> <td>21,929</td> <td>-2%</td> <td>7%</td>	umption of raw materials	20,244	21,602	20,043	20,634	22,368	23,131	22,195	20,501	21,929	-2%	7%
as % of sales17.8%16.5%16.3%16.8%16.9%16.3%16.2%17.6%17.Other expenditure1251714052144961537415316154021168612690123as % of sales23.3%24.1%24.9%26.8%24.2%23.1%17.7%20.6%18.EBITDA11,43413,02314,07611,73714,93917,33817,47513,15917,7Margins (%)21.3%22.3%24.2%20.5%23.6%26.0%26.5%21.4%25.Depreciation2,5442,9942,7213,4622,3922,9002,3342,8832,4Other income1,0341,2301,1441,3461,3631,7631,8462,4931,6Interest1782563183441642583011767PBT9,74611,00412,1819,27813,74615,94216,68612,59316,7Total tax2,6803,0264,1002,2233,7804,3844,0533,2494,3Tax rate (%)27.5%27.5%27.5%27.5%27.5%27.5%27.5%27.6%23.4%9,39011,7Minority interest(MI)-202-89-7125-9-24914646Adj. PAT before extraordinary items6,8647,8898,0107,0819,95711,30912,6349,39011,7No	of sales	37.7%	37.1%	34.5%	36.0%	35.3%	34.6%	33.6%	33.3%	32.8%		
Other expenditure1251714052144961537415316154021168612690123as % of sales23.3%24.1%24.9%26.8%24.2%23.1%17.7%20.6%18.EBITDA11,43413,02314,07611,73714,93917,33817,47513,15917,7Margins (%)21.3%22.3%24.2%20.5%23.6%26.0%26.5%21.4%25.Depreciation2,5442,9942,7213,4622,3922,9002,3342,8832,4Other income1,0341,2301,1441,3461,3631,7631,8462,4931,6Interest1782563183441642583011767PBT9,74611,00412,1819,27813,74615,94216,68612,59316,7Total tax2,6803,0264,1002,2233,7804,3844,0533,2494,7PAT before MI7,0667,9788,0817,0559,96611,55812,6339,34411,7Minority interest(MI)-202-89-7125-9-249146Adj. PAT before extraordinary items6,8647,8898,0107,0819,95711,30912,6349,39011,7No. of shares806.9807.0807.1807.2807.3807.6807.680	oyee costs	9,557	9,608	9,487	9,648	10,666	10,911	10,681	10,842	11,942	12%	10%
as % of sales23.3%24.1%24.9%26.8%24.2%23.1%17.7%20.6%18.EBITDA11,43413,02314,07611,73714,93917,33817,47513,15917,7Margins (%)21.3%22.3%24.2%20.5%23.6%26.0%26.5%21.4%25.Depreciation2,5442,9942,7213,4622,3922,9002,3342,8832,4Other income1,0341,2301,1441,3461,3631,7631,8462,4931,6Interest178256318344164258301176PBT9,74611,00412,1819,27813,74615,94216,68612,59316,7Total tax2,6803,0264,1002,2233,7804,3844,0533,2494,5Tax rate (%)27.5%27.5%33.7%24.0%27.5%27.5%25.8%27.PAT before MI7,0667,9788,0817,0559,96611,55812,6339,34411,7Minority interest(MI)-202-89-7125-9-249146Adj. PAT before extraordinary items6,8647,8898,0107,0819,95711,30912,6349,39011,7No. of shares806.9807.0807.1807.2807.3807.6807.680	of sales	17.8%	16.5%	16.3%	16.8%	16.9%	16.3%	16.2%	17.6%	17.8%		
EBITDA11,43413,02314,07611,73714,93917,33817,47513,15917,Margins (%)21.3%22.3%24.2%20.5%23.6%26.0%26.5%21.4%25.Depreciation2,5442,9942,7213,4622,3922,9002,3342,8832,4Other income1,0341,2301,1441,3461,3631,7631,8462,4931,6Interest1782563183441642583011767PBT9,74611,00412,1819,27813,74615,94216,68612,59316,7Total tax2,6803,0264,1002,2233,7804,3844,0533,2494,5Tax rate (%)27.5%27.5%33.7%24.0%27.5%27.5%25.8%27.PAT before MI7,0667,9788,0817,0559,96611,55812,6339,34411,7Minority interest(MI)-202-89-7125-9-249146Adj. PAT before extraordinary items6,8647,8898,0107,0819,95711,30912,6349,39011,7No. of shares806.9807.0807.1807.2807.3807.6807.680	rexpenditure	12517	14052	14496	15374	15316	15402	11686	12690	12380	-19%	-2%
Margins (%) 21.3% 22.3% 24.2% 20.5% 23.6% 26.0% 26.5% 21.4% 25. Depreciation 2,544 2,994 2,721 3,462 2,392 2,900 2,334 2,883 2,4 Other income 1,034 1,230 1,144 1,346 1,363 1,763 1,846 2,493 1,6 Interest 178 256 318 344 164 258 301 176 7 PBT 9,746 11,004 12,181 9,278 13,746 15,942 16,686 12,593 16,7 Total tax 2,680 3,026 4,100 2,223 3,780 4,384 4,053 3,249 4,3 Tax rate (%) 27.5% 27.5% 33.7% 24.0% 27.5% 27.5% 25.8% 27. PAT before MI 7,066 7,978 8,081 7,055 9,966 11,558 12,633 9,344 11,7 Minority interest(MI) <td< td=""><td>of sales</td><td>23.3%</td><td>24.1%</td><td>24.9%</td><td>26.8%</td><td>24.2%</td><td>23.1%</td><td>17.7%</td><td>20.6%</td><td>18.5%</td><td></td><td></td></td<>	of sales	23.3%	24.1%	24.9%	26.8%	24.2%	23.1%	17.7%	20.6%	18.5%		
Depreciation2,5442,9942,7213,4622,3922,9002,3342,8832,4Other income1,0341,2301,1441,3461,3631,7631,8462,4931,6Interest1782563183441642583011767PBT9,74611,00412,1819,27813,74615,94216,68612,59316,7Total tax2,6803,0264,1002,2233,7804,3844,0533,2494,7Tax rate (%)27.5%27.5%27.5%33.7%24.0%27.5%27.5%24.3%25.8%27.7PAT before MI7,0667,9788,0817,0559,96611,55812,6339,34411,7Minority interest(MI)-202-89-7125-9-249146Adj. PAT before extraordinary items6,8647,8898,0107,0819,95711,30912,6349,39011,7Extraordinary expenses00-1,82400-1,9480No. of shares806.9807.0807.1807.2807.2807.3807.6807.680	DA	11,434	13,023	14,076	11,737	14,939	17,338	17,475	13,159	17,158	15%	30%
Other income1,0341,2301,1441,3461,3631,7631,8462,4931,6Interest178256318344164258301176PBT9,74611,00412,1819,27813,74615,94216,68612,59316,7Total tax2,6803,0264,1002,2233,7804,3844,0533,2494,5Tax rate (%)27.5%27.5%33.7%24.0%27.5%27.5%24.3%25.8%27.7PAT before MI7,0667,9788,0817,0559,96611,55812,6339,34411,7Minority interest(MI)-202-89-7125-9-249146Adj. PAT before extraordinary items6,8647,8898,0107,0819,95711,30912,6349,39011,7Extraordinary expenses000-1,82400-1,9480Reported PAT6,8647,8898,0105,2579,95711,30910,6869,39011,7No. of shares806.9807.0807.1807.2807.3807.6807.6807	ins (%)	21.3%	22.3%	24.2%	20.5%	23.6%	26.0%	26.5%	21.4%	25.6%		
Interest178256318344164258301176PBT9,74611,00412,1819,27813,74615,94216,68612,59316,7Total tax2,6803,0264,1002,2233,7804,3844,0533,2494,3Tax rate (%)27.5%27.5%27.5%27.5%27.5%24.3%25.8%27.PAT before MI7,0667,9788,0817,0559,96611,55812,6339,34411,7Minority interest(MI)-202-89-7125-9-249146Adj. PAT before extraordinary items6,8647,8898,0107,0819,95711,30912,6349,39011,7Extraordinary expenses00-1,82400-1,9480Reported PAT6,8647,8898,0105,2579,95711,30910,6869,39011,7No. of shares806.9807.0807.1807.2807.2807.3807.6807.6807	eciation	2,544	2,994	2,721	3,462	2,392	2,900	2,334	2,883	2,467		
PBT9,74611,00412,1819,27813,74615,94216,68612,59316,7Total tax2,6803,0264,1002,2233,7804,3844,0533,2494,2Tax rate (%)27.5%27.5%27.5%33.7%24.0%27.5%27.5%24.3%25.8%27.PAT before MI7,0667,9788,0817,0559,96611,55812,6339,34411,7Minority interest(MI)-202-89-7125-9-249146Adj. PAT before extraordinary items6,8647,8898,0107,0819,95711,30912,6349,39011,7Extraordinary expenses00-1,82400-1,94800Reported PAT6,8647,8898,0105,2579,95711,30910,6869,39011,7No. of shares806.9807.0807.1807.2807.2807.3807.6807.6807	rincome	1,034	1,230	1,144	1,346	1,363	1,763	1,846	2,493	1,602		
Total tax2,6803,0264,1002,2233,7804,3844,0533,2494,3Tax rate (%)27.5%27.5%27.5%33.7%24.0%27.5%27.5%24.3%25.8%27.PAT before MI7,0667,9788,0817,0559,96611,55812,6339,34411,7Minority interest(MI)-202-89-7125-9-249146Adj. PAT before extraordinary items6,8647,8898,0107,0819,95711,30912,6349,39011,7Extraordinary expenses00-1,82400-1,9480Reported PAT6,8647,8898,0105,2579,95711,30910,6869,39011,7No. of shares806.9807.0807.1807.2807.2807.3807.6807.6807	est	178	256	318	344	164	258	301	176	180		
Tax rate (%)27.5%27.5%33.7%24.0%27.5%27.5%24.3%25.8%27.PAT before MI7,0667,9788,0817,0559,96611,55812,6339,34411,7Minority interest(MI)-202-89-7125-9-249146Adj. PAT before extraordinary items6,8647,8898,0107,0819,95711,30912,6349,39011,7Extraordinary expenses00-1,82400-1,9480Reported PAT6,8647,8898,0105,2579,95711,30910,6869,39011,7No. of shares806.9807.0807.1807.2807.2807.3807.6807.6807		9,746	11,004	12,181	9,278	13,746	15,942	16,686	12,593	16,114	17%	28%
PAT before MI 7,066 7,978 8,081 7,055 9,966 11,558 12,633 9,344 11,7 Minority interest(MI) -202 -89 -71 25 -9 -249 1 46 Adj. PAT before extraordinary items 6,864 7,889 8,010 7,081 9,957 11,309 12,634 9,390 11,7 Extraordinary expenses 0 0 -1,824 0 0 -1,948 0 Reported PAT 6,864 7,889 8,010 5,257 9,957 11,309 10,686 9,390 11,7 No. of shares 806.9 807.0 807.1 807.2 807.3 807.6 807.6 807	tax	2,680	3,026	4,100	2,223	3,780	4,384	4,053	3,249	4,351		
Minority interest(MI) -202 -89 -71 25 -9 -249 1 46 Adj. PAT before extraordinary items 6,864 7,889 8,010 7,081 9,957 11,309 12,634 9,390 11,7 Extraordinary expenses 0 0 0 -1,824 0 0 -1,948 0 Reported PAT 6,864 7,889 8,010 5,257 9,957 11,309 10,686 9,390 11,7 No. of shares 806.9 807.0 807.1 807.2 807.3 807.6 807.6 807	ate (%)	27.5%	27.5%	33.7%	24.0%	27.5%	27.5%	24.3%	25.8%	27.0%		
Adj. PAT before extraordinary items6,8647,8898,0107,0819,95711,30912,6349,39011,7Extraordinary expenses00-1,82400-1,9480Reported PAT6,8647,8898,0105,2579,95711,30910,6869,39011,7No. of shares806.9807.0807.1807.2807.2807.3807.6807.680	before MI	7,066	7,978	8,081	7,055	9,966	11,558	12,633	9,344	11,763	18%	26%
Extraordinary expenses 0 0 0 -1,824 0 0 -1,948 0 Reported PAT 6,864 7,889 8,010 5,257 9,957 11,309 10,686 9,390 11,7 No. of shares 806.9 807.0 807.1 807.2 807.3 807.6 807.6 80	rity interest(MI)	-202	-89	-71	25	-9	-249	1	46	14		
Reported PAT 6,864 7,889 8,010 5,257 9,957 11,309 10,686 9,390 11,7 No. of shares 806.9 807.0 807.1 807.2 807.2 807.3 807.6 807.6 80	PAT before extraordinary items	6,864	7,889	8,010	7,081	9,957	11,309	12,634	9,390	11,776	18%	25%
No. of shares 806.9 807.0 807.1 807.2 807.2 807.3 807.6 807.6 80	ordinary expenses	0	0	0	-1,824	0	0	-1,948	0	0		
	rted PAT	6,864	7,889	8,010	5,257	9,957	11,309	10,686	9,390	11,776	18%	25%
	f shares	806.9	807.0	807.1	807.2	807.2	807.3	807.6	807.6	808.0		
EPS 8.5 9.8 9.9 8.8 12.3 14.0 15.6 11.6 1		8.5	9.8	9.9	8.8	12.3	14.0	15.6	11.6	14.6		
Core EPS 7.6 8.7 9.0 7.5 11.1 12.4 13.9 9.3 1	EPS	7.6	8.7	9.0	7.5	11.1	12.4	13.9	9.3	13.1		

Figure 2: Revenue break-u	р										
(Rsm)	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	Y-o-Y (%)	Q-o-Q (%)
North America INR	11,990	14,320	16,000	16,770	18,220	18,870	19,160	18,750	20,870	15%	11%
% total revenue	22.3%	24.6%	27.5%	29.2%	28.8%	28.3%	29.3%	30.4%	31.2%		
Global Access & Rest of Africa	2,200	2,690	1,300	750	2,740	3,730	2,120	710	510	-81%	-28%
% total revenue	4.1%	4.6%	2.2%	1.3%	4.3%	5.6%	3.2%	1.2%	0.8%		
South Africa	5,680	5,980	5,500	6,180	5,140	6,200	6,030	6,900	6,260	22%	-9%
% total revenue	10.6%	10.3%	9.5%	10.8%	8.1%	9.3%	9.2%	11.2%	9.4%		
India	24,830	25,630	25,630	22,590	27,720	28,170	28,590	24,170	28,980	5%	20%
% total revenue	46.2%	44.0%	44.1%	39.4%	43.8%	42.2%	43.7%	39.2%	43.3%		
EM & Europe	7,200	7,630	7,620	7,840	7,790	7,340	7,460	8,270	8,490	9%	3%
% total revenue	13.4%	13.1%	13.1%	13.7%	12.3%	11.0%	11.4%	13.4%	12.7%		
API	1,350	1,530	1,470	1,340	1,360	1,470	1,080	1,890	980	-28%	-48%
% total revenue	2.5%	2.6%	2.5%	2.3%	2.1%	2.2%	1.7%	3.1%	1.5%		
Others	502	505	581	1,923	319	1,002	990	940	849	166%	-10%
% total revenue	0.9%	0.9%	1.0%	3.4%	0.5%	1.5%	1.5%	1.5%	1.3%		
Total Revenue	53,752	58,285	58,101	57,393	63,289	66,782	65,430	61,630	66,939	6%	9%
							SC	DURCE: INCRE	D RESEARC	H, COMPAN	Y REPORTS


Figure 3: Margin profile											
(Rsm)	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25 Y-	o-Y (bp) Q-	o-Q (bp)
Margins (%)											
Gross	62%	63%	66%	64%	65%	65%	66%	67%	67%	258	50
EBITDA	21%	22%	24%	20%	24%	26%	26%	21%	26%	203	428
Adj.PAT	13%	14%	14%	12%	16%	17%	19%	15%	18%	186	236
Effective tax rate	27%	28%	34%	24%	28%	27%	24%	26%	27%	-50	120
								SOURCE: INCF	RED RESEARCH	I, COMPANY I	REPORTS

Figure 4: Actuals versus estimates					
	Actuals	Incred Estimates	Variance (%) Bloom	berg Estimates	Variance (%)
Revenue (Rsm)	66,939	67,490	-0.0	67,919	-1.4
EBITDA (Rsm)	17,158	16,581	3.5	16,689	2.8
Margin (%)	25.6	24.6		24.6	
PAT (Rsm)	11,776	11,354	3.7	11,218	5.0
			SOURCE: IN	NCRED RESEARCH, C	OMPANY REPORTS

Figure 5: Changes in our ear	nings estimates (Rsm)					
		FY25F			FY26F	
	Old	New	Change (%)	Old	New	Change (%)
Revenue	2,73,873	2,75,057	0.4	2,97,669	2,99,651	0.7
EBITDA	67,047	69,283	3.3	75,028	76,571	2.1
Margin (%)	24.5	25.2		25.2	25.6	
PAT	44,553	46,294	3.9	50,013	51,140	2.3
EPS	55.1	57.3	3.9	61.8	63.2	2.3
				SOURCE IN	NCRED RESEARCH, C	OMPANY REPORTS

InCred Equities

Pharmaceuticals | India Cipla Ltd | July 27, 2024



Profit & Loss

(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Total Net Revenues	217,633	227,531	257,741	275,057	299,651
Gross Profit	132,677	145,008	169,545	181,247	195,689
Operating EBITDA	44,953	50,270	62,910	69,283	76,571
Depreciation And Amortisation	(10,520)	(11,721)	(10,510)	(11,500)	(12,500)
Operating EBIT	34,433	38,549	52,400	57,783	64,071
Financial Income/(Expense)	(1,064)	(1,095)	(899)	(750)	(900)
Pretax Income/(Loss) from Assoc.					
Non-Operating Income/(Expense)	2,809	4,755	7,466	7,000	7,500
Profit Before Tax (pre-El)	36,179	42,208	58,967	64,033	70,671
Exceptional Items	(1,246)	(1,824)	(1,948)		
Pre-tax Profit	34,933	40,384	57,019	64,033	70,671
Taxation	(9,338)	(12,029)	(15,466)	(17,289)	(19,081)
Exceptional Income - post-tax					
Profit After Tax	25,595	28,355	41,553	46,744	51,590
Minority Interests	(427)	(336)	(211)	(450)	(450)
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	25,168	28,019	41,343	46,294	51,140
Recurring Net Profit	26,081	29,300	42,762	46,294	51,140
Fully Diluted Recurring Net Profit	26,081	29,300	42,762	46,294	51,140

Cash Flow					
(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
EBITDA	44,953	50,270	62,910	69,283	76,571
Cash Flow from Invt. & Assoc.					
Change In Working Capital	(1,775)	(5,594)	(8,061)	30,737	(9,460)
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense					
Other Operating Cashflow	(9,919)	(12,299)	(13,510)	(17,739)	(19,531)
Net Interest (Paid)/Received	(1,064)	(1,095)	(899)	(750)	(900)
Tax Paid	(12,240)	(15,958)	(20,077)	(23,989)	(26,131)
Cashflow From Operations	33,259	32,377	41,339	82,282	47,580
Capex	(6,990)	(11,355)	(13,151)	(15,000)	(10,000)
Disposals Of FAs/subsidiaries					
Acq. Of Subsidiaries/investments		(251)	(420)		
Other Investing Cashflow					
Cash Flow From Investing	26,270	20,770	27,768	67,282	37,580
Debt Raised/(repaid)					
Proceeds From Issue Of Shares		1			
Shares Repurchased					
Dividends Paid	(4,034)	(4,035)	(6,862)	(4,442)	(4,848)
Preferred Dividends					
Other Financing Cashflow	(16,928)	436	(109)	7,723	7,526
Cash Flow From Financing	(20,961)	(3,598)	(6,970)	3,282	2,678
Total Cash Generated	5,308	17,172	20,798	70,563	40,258
Free Cashflow To Equity	59,529	53,147	69,107	149,563	85,160
Free Cashflow To Firm	60,592	54,242	70,006	150,313	86,060

SOURCE: INCRED RESEARCH, COMPANY REPORTS

BY THE NUMBERS...cont'd

(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Total Cash And Equivalents	19,321	15,722	8,752	79,315	119,573
Total Debtors	34,244	40,570	47,707	55,011	59,930
Inventories	53,502	51,564	52,380	60,513	65,923
Total Other Current Assets	40,041	64,893	85,576	41,259	44,948
Total Current Assets	147,108	172,750	194,414	236,098	290,375
Fixed Assets	56,087	57,398	60,469	63,969	61,469
Total Investments	3,556	5,725	6,422	6,422	6,422
Intangible Assets	48,408	45,140	47,130	47,130	47,130
Total Other Non-Current Assets	15,852	13,620	18,743	18,743	18,743
Total Non-current Assets	123,903	121,883	132,764	136,264	133,764
Short-term Debt	4,816	5,204	2,470	2,470	2,470
Current Portion of Long-Term Debt					
Total Creditors	25,081	24,571	24,740	28,803	31,336
Other Current Liabilities	19,235	21,323	25,248	23,042	25,069
Total Current Liabilities	49,132	51,097	52,458	54,316	58,874
Total Long-term Debt	5,745	2,088	2,254	3,727	4,653
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities	4,960	4,313	4,443	4,443	4,443
Total Non-current Liabilities	10,705	6,401	6,697	8,170	9,096
Total Provisions					
Total Liabilities	59,837	57,497	59,155	62,486	67,971
Shareholders Equity	208,417	234,078	267,064	308,467	354,309
Minority Interests	2,757	3,058	959	1,409	1,859
Total Equity	211,174	237,135	268,023	309,876	356,168
Key Ratios					
	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Revenue Growth	14.1%	4.5%	13.3%	6.7%	8.9%
Operating EBITDA Growth	7.7%	11.8%	25.1%	10.1%	10.5%
Operating EBITDA Margin	20.7%	22.1%	24.4%	25.2%	25.6%
Net Cash Per Share (Rs)	10.85	10.45	4.99	90.60	139.34
			330.93	382.24	439.04
BVPS (Rs)	258.26	290.06	330.93	302.24	
	258.26 32.38	290.06 35.19	58.30	77.04	
BVPS (Rs)					71.19
BVPS (Rs) Gross Interest Cover	32.38	35.19	58.30	77.04	71.19
BVPS (Rs) Gross Interest Cover Effective Tax Rate	32.38	35.19	58.30	77.04	71.19
BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio	32.38 26.7%	35.19 29.8%	58.30 27.1%	77.04 27.0%	71.19 27.0% 70.00
BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days	32.38 26.7% 57.61	35.19 29.8% 60.01	58.30 27.1% 62.51	77.04 27.0% 68.15	71.19 27.0% 70.00 221.95
BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days	32.38 26.7% 57.61 215.23	35.19 29.8% 60.01 232.36	58.30 27.1% 62.51 215.09	77.04 27.0% 68.15 219.62	71.19 27.0% 70.00 221.95 105.57
BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days	32.38 26.7% 57.61 215.23 98.28	35.19 29.8% 60.01 232.36 109.80	58.30 27.1% 62.51 215.09 102.04	77.04 27.0% 68.15 219.62 104.16	71.19 27.0% 70.00 221.95 105.57 19.8% 18.9%

SOURCE: INCRED RESEARCH, COMPANY REPORTS

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd.(formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which are believed to be accurate and complete and obtained through reliable public or other nonconfidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

InCred Equities

Pharmaceuticals | India Cipla Ltd | July 27, 2024

	Analyst/ Relative	Entity/ Associates
any financial interests in the company covered in this report (subject company) and nature of such financial interest	NO	NO
actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;	NO	NO
any other material conflict of interest at the time of publication of the research report or at the time of public appearance	NO	NO
received any compensation from the subject company in the past twelve months for investment banking or merchant banking or brokerage services or investment advisory or depository or distribution from the subject company in the last twelve months for products/services other than investment banking or merchant banking or broker- age services or investment advisory or depository or distribution from the subject company in the last twelve months	NO	NO
managed or co-managed public offering of securities for the subject company in the last twelve months	NO	NO
received any compensation or other benefits from the subject company or third party in connection with the research report	NO	NO
served as an officer, director or employee of the subject company	NO	NO
been engaged in market making activity for the subject company	NO	NO

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in thisreport and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.